Hardware, Equipment & Parts
Build Your Comparison
Side-by-side financial analysisStock Comparison
ALNT vs EMR vs ROK vs AME vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
Industrial - Machinery
Industrial - Machinery
Banks - Diversified
ALNT vs EMR vs ROK vs AME vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Hardware, Equipment & Parts | Industrial - Machinery | Industrial - Machinery | Industrial - Machinery | Banks - Diversified |
| Market Cap | $1.55B | $80.13B | $51.61B | $52.03B | $896.00B |
| Revenue (TTM) | $561M | $18.32B | $8.80B | $7.60B | $280.33B |
| Net Income (TTM) | $24M | $2.44B | $1.09B | $1.53B | $57.05B |
| Gross Margin | 31.2% | 52.7% | 52.5% | 36.6% | 60.0% |
| Operating Margin | 8.4% | 19.8% | 19.1% | 26.2% | 25.9% |
| Forward P/E | 36.2x | 22.0x | 35.5x | 27.9x | 14.4x |
| Total Debt | $197M | $13.76B | $3.65B | $2.28B | $942.38B |
| Cash & Equiv. | $41M | $1.54B | $468M | $458M | $343.34B |
ALNT vs EMR vs ROK vs AME vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Allient Inc. (ALNT) | 100 | 258.8 | +158.8% |
| Emerson Electric Co. (EMR) | 100 | 230.6 | +130.6% |
| Rockwell Automation… (ROK) | 100 | 215.7 | +115.7% |
| AMETEK, Inc. (AME) | 100 | 254.1 | +154.1% |
| JPMorgan Chase & Co. (JPM) | 100 | 341.0 | +241.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALNT vs EMR vs ROK vs AME vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ALNT ranks third and is worth considering specifically for momentum.
- +166.9% vs EMR's +14.6%
Among these 5 stocks, EMR doesn't own a clear edge in any measured category.
ROK is the clearest fit if your priority is efficiency.
- 9.7% ROA vs JPM's 1.3%, ROIC 15.1% vs 4.5%
AME is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 6.6%, EPS growth 7.9%, 3Y rev CAGR 6.4%
- Lower volatility, beta 0.93, Low D/E 21.5%, current ratio 1.06x
- Beta 0.93, yield 0.5%, current ratio 1.06x
- 6.6% revenue growth vs ROK's 1.0%
JPM carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 15 yrs, beta 0.94, yield 1.9%
- 465.8% 10Y total return vs ALNT's 314.8%
- PEG 0.81 vs ALNT's 5.32
- Lower P/E (14.4x vs 27.9x), PEG 0.81 vs 2.50
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 6.6% revenue growth vs ROK's 1.0% | |
| Value | Lower P/E (14.4x vs 27.9x), PEG 0.81 vs 2.50 | |
| Quality / Margins | 20.4% margin vs ALNT's 4.3% | |
| Stability / Safety | Beta 0.93 vs ALNT's 2.10, lower leverage | |
| Dividends | 1.9% yield, 15-year raise streak, vs EMR's 1.5% | |
| Momentum (1Y) | +166.9% vs EMR's +14.6% | |
| Efficiency (ROA) | 9.7% ROA vs JPM's 1.3%, ROIC 15.1% vs 4.5% |
ALNT vs EMR vs ROK vs AME vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ALNT vs EMR vs ROK vs AME vs JPM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 2 of 6 categories
ROK leads 1 • ALNT leads 0 • EMR leads 0 • AME leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 500.1x ALNT's $561M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to ALNT's 4.3%. On growth, ROK holds the edge at +11.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $561M | $18.3B | $8.8B | $7.6B | $280.3B |
| EBITDAEarnings before interest/tax | $72M | $4.7B | $1.9B | $2.3B | $81.4B |
| Net IncomeAfter-tax profit | $24M | $2.4B | $1.1B | $1.5B | $57.0B |
| Free Cash FlowCash after capex | $41M | $3.1B | $1.3B | $1.7B | $100.9B |
| Gross MarginGross profit ÷ Revenue | +31.2% | +52.7% | +52.5% | +36.6% | +60.0% |
| Operating MarginEBIT ÷ Revenue | +8.4% | +19.8% | +19.1% | +26.2% | +25.9% |
| Net MarginNet income ÷ Revenue | +4.3% | +13.3% | +12.4% | +20.1% | +20.4% |
| FCF MarginFCF ÷ Revenue | +7.3% | +17.0% | +15.2% | +22.4% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.6% | +2.9% | +11.8% | +11.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +52.4% | +28.2% | +39.6% | +14.5% | +16.0% |
Valuation Metrics
JPM leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 16.0x trailing earnings, JPM trades at a 77% valuation discount to ALNT's 69.2x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs ALNT's 10.18x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.6B | $80.1B | $51.6B | $52.0B | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $1.7B | $92.3B | $54.8B | $53.9B | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | 69.22x | 35.41x | 59.89x | 35.49x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | 36.19x | 21.99x | 35.52x | 27.90x | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | 10.18x | 7.84x | — | 3.18x | 0.90x |
| EV / EBITDAEnterprise value multiple | 23.27x | 18.29x | 31.34x | 28.65x | 18.36x |
| Price / SalesMarket cap ÷ Revenue | 2.80x | 4.45x | 6.19x | 7.03x | 3.20x |
| Price / BookPrice ÷ Book value/share | 5.07x | 3.99x | 14.00x | 4.94x | 2.47x |
| Price / FCFMarket cap ÷ FCF | 31.26x | 30.05x | 38.00x | 31.12x | 8.88x |
Profitability & Efficiency
ROK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ROK delivers a 29.6% return on equity — every $100 of shareholder capital generates $30 in annual profit, vs $8 for ALNT. AME carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), ROK scores 8/9 vs JPM's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +8.0% | +12.1% | +29.6% | +14.4% | +15.9% |
| ROA (TTM)Return on assets | +4.1% | +5.8% | +9.7% | +9.6% | +1.3% |
| ROICReturn on invested capital | +7.7% | +8.2% | +15.1% | +12.1% | +4.5% |
| ROCEReturn on capital employed | +9.4% | +10.0% | +18.5% | +15.0% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 8 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.65x | 0.68x | 0.98x | 0.21x | 2.60x |
| Net DebtTotal debt minus cash | $156M | $12.2B | $3.2B | $1.8B | $599.0B |
| Cash & Equiv.Liquid assets | $41M | $1.5B | $468M | $458M | $343.3B |
| Total DebtShort + long-term debt | $197M | $13.8B | $3.6B | $2.3B | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | 2.31x | 6.46x | 9.06x | 23.34x | 0.74x |
Total Returns (Dividends Reinvested)
Evenly matched — ALNT and JPM each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALNT five years ago would be worth $25,019 today (with dividends reinvested), compared to $15,772 for EMR. Over the past 12 months, ALNT leads with a +166.9% total return vs EMR's +14.6%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs AME's 15.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +64.5% | +6.2% | +15.9% | +8.8% | -0.5% |
| 1-Year ReturnPast 12 months | +166.9% | +14.6% | +43.0% | +26.9% | +21.8% |
| 3-Year ReturnCumulative with dividends | +136.9% | +77.8% | +53.3% | +52.3% | +138.2% |
| 5-Year ReturnCumulative with dividends | +150.2% | +57.7% | +71.8% | +70.4% | +118.2% |
| 10-Year ReturnCumulative with dividends | +314.8% | +216.5% | +333.4% | +397.2% | +465.8% |
| CAGR (3Y)Annualised 3-year return | +33.3% | +21.1% | +15.3% | +15.1% | +33.6% |
Risk & Volatility
Evenly matched — ROK and AME each lead in 1 of 2 comparable metrics.
Risk & Volatility
AME is the less volatile stock with a 0.93 beta — it tends to amplify market swings less than ALNT's 2.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ROK currently trades 98.1% from its 52-week high vs EMR's 86.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.10x | 1.61x | 1.52x | 0.93x | 0.94x |
| 52-Week HighHighest price in past year | $95.65 | $165.15 | $468.11 | $243.18 | $337.25 |
| 52-Week LowLowest price in past year | $33.02 | $122.64 | $305.44 | $174.43 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +95.5% | +86.6% | +98.1% | +93.4% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 70.7 | 53.9 | 56.0 | 48.6 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 217K | 2.5M | 623K | 1.0M | 7.0M |
Analyst Outlook
Evenly matched — EMR and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ALNT as "Buy", EMR as "Buy", ROK as "Hold", AME as "Buy", JPM as "Buy". Consensus price targets imply 14.4% upside for EMR (target: $164) vs -15.9% for ALNT (target: $77). For income investors, JPM offers the higher dividend yield at 1.86% vs ALNT's 0.13%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $76.80 | $163.62 | $468.63 | $248.50 | $339.75 |
| # AnalystsCovering analysts | 5 | 41 | 39 | 29 | 61 |
| Dividend YieldAnnual dividend ÷ price | +0.1% | +1.5% | +1.1% | +0.5% | +1.9% |
| Dividend StreakConsecutive years of raises | 0 | 54 | 16 | 6 | 15 |
| Dividend / ShareAnnual DPS | $0.12 | $2.10 | $5.23 | $1.23 | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.6% | +0.8% | +0.8% | +3.9% |
JPM leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). ROK leads in 1 (Profitability & Efficiency). 3 tied.
ALNT vs EMR vs ROK vs AME vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ALNT or EMR or ROK or AME or JPM a better buy right now?
For growth investors, AMETEK, Inc.
(AME) is the stronger pick with 6. 6% revenue growth year-over-year, versus 1. 0% for Rockwell Automation, Inc. (ROK). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Allient Inc. (ALNT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ALNT or EMR or ROK or AME or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 0x versus Allient Inc. at 69. 2x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Allient Inc. 's 5. 32x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ALNT or EMR or ROK or AME or JPM?
Over the past 5 years, Allient Inc.
(ALNT) delivered a total return of +150. 2%, compared to +57. 7% for Emerson Electric Co. (EMR). Over 10 years, the gap is even starker: JPM returned +465. 8% versus EMR's +216. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ALNT or EMR or ROK or AME or JPM?
By beta (market sensitivity over 5 years), AMETEK, Inc.
(AME) is the lower-risk stock at 0. 93β versus Allient Inc. 's 2. 10β — meaning ALNT is approximately 126% more volatile than AME relative to the S&P 500. On balance sheet safety, AMETEK, Inc. (AME) carries a lower debt/equity ratio of 21% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — ALNT or EMR or ROK or AME or JPM?
By revenue growth (latest reported year), AMETEK, Inc.
(AME) is pulling ahead at 6. 6% versus 1. 0% for Rockwell Automation, Inc. (ROK). On earnings-per-share growth, the picture is similar: Allient Inc. grew EPS 67. 1% year-over-year, compared to -7. 4% for Rockwell Automation, Inc.. Over a 3-year CAGR, EMR leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ALNT or EMR or ROK or AME or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus 4. 0% for Allient Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AME leads at 26. 2% versus 8. 7% for ALNT. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ALNT or EMR or ROK or AME or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Allient Inc. 's 5. 32x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 36. 2x for Allient Inc. — 21. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EMR: 14. 4% to $163. 62.
08Which pays a better dividend — ALNT or EMR or ROK or AME or JPM?
All stocks in this comparison pay dividends.
JPMorgan Chase & Co. (JPM) offers the highest yield at 1. 9%, versus 0. 1% for Allient Inc. (ALNT).
09Is ALNT or EMR or ROK or AME or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Allient Inc. (ALNT) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, ALNT: +314. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ALNT and EMR and ROK and AME and JPM?
These companies operate in different sectors (ALNT (Technology) and EMR (Industrials) and ROK (Industrials) and AME (Industrials) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ALNT is a small-cap quality compounder stock; EMR is a mid-cap quality compounder stock; ROK is a mid-cap quality compounder stock; AME is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. EMR, ROK, AME, JPM pay a dividend while ALNT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.